Delayed-Release Phosphatidylcholine Is Effective for Treatment of Ulcerative Colitis: A Meta-Analysis
| العنوان: | Delayed-Release Phosphatidylcholine Is Effective for Treatment of Ulcerative Colitis: A Meta-Analysis |
|---|---|
| المؤلفون: | Wolfgang Stremmel, Ralf Weiskirchen, Huseyin Vural, Osman Evliyaoglu |
| المصدر: | Digestive Diseases. 39:508-515 |
| بيانات النشر: | S. Karger AG, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | medicine.medical_specialty, education.field_of_study, business.industry, Population, Gastroenterology, General Medicine, Odds ratio, Placebo, medicine.disease, Ulcerative colitis, law.invention, Clinical trial, Randomized controlled trial, law, Internal medicine, Meta-analysis, medicine, Adverse effect, education, business |
| الوصف: | Background: Phosphatidylcholine (PC) is intrinsically missing in intestinal mucus of patients with ulcerative colitis. Topical supplementation with delayed intestinal release PC formulations is assumed to compensate this lack. Three monocenter randomized controlled trials (RCTs) with a 30% PC-containing lecithin were successful, whereas 1 trial with >94% PC-containing lecithin failed. Objectives: Evaluation of 30% PC-containing lecithin provided in a delayed intestinal release formulation for treatment efficacy of ulcerative colitis was evaluated by meta-analysis of 3 RCTs. Methods: Meta-analysis of 3 studies was performed using RevMan 5.3 software. Odds ratio (OR) and 95% Cl were calculated for remission, clinical and endoscopic improvement, histology, and life quality. p values Results: The meta-analysis of 3 RTCs with 160 included patients with ulcerative colitis verified that PC improved the rate of remission (OR = 9.68), as well as clinical (OR = 30.58) and endoscopic outcomes (OR = 36.73). Within the available patient population, also histology and quality of life became better. All effects were significant over placebo. Achieved remission was maintained in a higher percentage of patients under intestinal-release PC formulation than placebo. The profile of adverse events was identical to the placebo population. Conclusions: A 30% PC-containing lecithin in delayed intestinal release formulation improves clinical and endoscopic outcomes, histologic activity, and quality of life in patients with ulcerative colitis. For the patients, lack of adverse events is an important consideration. |
| تدمد: | 1421-9875 0257-2753 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::b07345753b20749ce3045ad539227c9fTest https://doi.org/10.1159/000514355Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi...........b07345753b20749ce3045ad539227c9f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14219875 02572753 |
|---|